Novel applications of recombinant erythropoietin.
Recombinant erythropoietin (EPO) was introduced into clinical practice after the identification of EPO as the major haemopoietic growth factor determining survival and maturation of erythroid precursors. Advances in our understanding of the novel sites of action of EPO in the vasculature, brain, heart and kidney have opened new avenues of therapeutic potential for EPO, and have led to an increased understanding of the biological roles of EPO and its mechanisms of cell protection.
Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK.
Edward J
EJ
Sharples
Christoph
C
Thiemermann
Magdi M
MM
Yaqoob
D000818:Animals; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin